VA
HLVX

VR Adviser’s HilleVax HLVX Stock Holding History

VR Adviser’s Portfolio HLVX Stock Details HLVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,075,000
Closed -$34.5M – 39
2024
Q1 		$34.5M Hold
2,075,000
– – 1.64% 18
2023
Q4 		$33.3M Buy
2,075,000
+37,687
+2% +$501K 2.28% 12
2023
Q3 		$27.4M Buy
+2,037,313
New +$28.7M 2.88% 13

Other funds holding HLVX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return

VR Adviser's HLVX Position: Q2 2024 in Review

VR Adviser sold out of HilleVax (HLVX) in Q2 2024, closing a stake of 2,075,000 shares — an estimated $34.5M sold.

VR Adviser first reported a position in HLVX in Q3 2023 and held it in 3 quarters. The position peaked at $34.5M in Q1 2024. 93 funds tracked by Wall St. Rank hold HLVX as of Q2 2024.

  • VR Adviser reported no remaining HilleVax position as of Q2 2024 after selling out during the quarter.
  • VR Adviser sold 2,075,000 HilleVax shares in Q2 2024, an estimated $34.5M.
  • VR Adviser first reported a position in HilleVax in Q3 2023 and held it in 3 quarters.
  • VR Adviser's HilleVax position peaked at $34.5M in Q1 2024.
  • 93 funds tracked by Wall St. Rank held HilleVax as of Q2 2024.

Based on VR Adviser's 13F filing for Q2 2024, filed 14 Aug 2024.